國立虎尾科技大學 |

Toward the Patient-Centered Development of Cancer Therapeutics : = A Focus on Nanomedicines.

Record Type:	Language materials, manuscript : Monograph/item
Title/Author:	Toward the Patient-Centered Development of Cancer Therapeutics :/
Reminder of title:	A Focus on Nanomedicines.
Author:	Freeman, Michael Welch.
Description:	1 online resource (130 pages)
Notes:	Source: Masters Abstracts International, Volume: 58-01.
Contained By:	Masters Abstracts International58-01(E).
Subject:	Biomedical engineering. -
Online resource:	click for full text (PQDT)
ISBN:	9780438184053

Toward the Patient-Centered Development of Cancer Therapeutics : = A Focus on Nanomedicines.
Freeman, Michael Welch.

Toward the Patient-Centered Development of Cancer Therapeutics :A Focus on Nanomedicines. - 1 online resource (130 pages)

Source: Masters Abstracts International, Volume: 58-01.

Thesis (M.A.S.)--University of Toronto (Canada), 2018.

Includes bibliographical references

Inspired by early work indicating nanometre-scale macromolecules can accumulate in tumours, nanomedicines were developed with intentions of improving cancer-killing efficacy and reducing systemic toxicity typical of traditional chemotherapies. This research first evaluates evidence provided to FDA and EMA regulators in order for cancer nanomedicines to be granted marketing approval, and then consults mature clinical data via health technology assessments to synthesize judgments of clinical benefit with respect to overall survival, safety, and health-related quality of life (HRQOL). Findings indicate that every marketed cancer nanomedicine--- eight of nine being liposome technologies---demonstrates comparative clinical benefit on at least one dimension, that improvements in overall survival frequently come at the expense of safety, and that HRQOL is generally conserved or improved versus comparator therapies. Sparse data and inconsistency in HRQOL reporting practices were major deficiencies among the documents consulted and represent key barriers to providing patients evidence that can inform treatment decision-making.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2018

Mode of access: World Wide Web

ISBN: 9780438184053Subjects--Topical Terms:

588770
Biomedical engineering.
Index Terms--Genre/Form:

554714
Electronic books.

Toward the Patient-Centered Development of Cancer Therapeutics : = A Focus on Nanomedicines.
LDR:02388ntm a2200349Ki 4500 001 918352
005 20181114145236.5
006 m o u
007 cr mn||||a|a||
008 190606s2018 xx obm 000 0 eng d
020 $a 9780438184053
035 $a (MiAaPQ)AAI10744580
035 $a (MiAaPQ)toronto:17174
035 $a AAI10744580
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Freeman, Michael Welch. $3 1192654
245 1 0 $a Toward the Patient-Centered Development of Cancer Therapeutics : $b A Focus on Nanomedicines.
264 0 $c 2018
300 $a 1 online resource (130 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Masters Abstracts International, Volume: 58-01.
500 $a Adviser: Christine J. Allen.
502 $a Thesis (M.A.S.)--University of Toronto (Canada), 2018.
504 $a Includes bibliographical references
520 $a Inspired by early work indicating nanometre-scale macromolecules can accumulate in tumours, nanomedicines were developed with intentions of improving cancer-killing efficacy and reducing systemic toxicity typical of traditional chemotherapies. This research first evaluates evidence provided to FDA and EMA regulators in order for cancer nanomedicines to be granted marketing approval, and then consults mature clinical data via health technology assessments to synthesize judgments of clinical benefit with respect to overall survival, safety, and health-related quality of life (HRQOL). Findings indicate that every marketed cancer nanomedicine--- eight of nine being liposome technologies---demonstrates comparative clinical benefit on at least one dimension, that improvements in overall survival frequently come at the expense of safety, and that HRQOL is generally conserved or improved versus comparator therapies. Sparse data and inconsistency in HRQOL reporting practices were major deficiencies among the documents consulted and represent key barriers to providing patients evidence that can inform treatment decision-making.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2018
538 $a Mode of access: World Wide Web
650 4 $a Biomedical engineering. $3 588770
650 4 $a Nanotechnology. $3 557660
650 4 $a Oncology. $3 593951
655 7 $a Electronic books. $2 local $3 554714
690 $a 0541
690 $a 0652
690 $a 0992
710 2 $a ProQuest Information and Learning Co. $3 1178819
710 2 $a University of Toronto (Canada). $b Chemical Engineering & Applied Chemistry. $3 1181092
773 0 $t Masters Abstracts International $g 58-01(E).
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10744580 $z click for full text (PQDT)